Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …

Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

Abstract The RAS–RAF–MEK–ERK signalling pathway is hyperactivated in a high
percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

The identification of mutationally activated BRAF in many cancers altered our conception of
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …

In the era of precision medicine, cancer therapy can be tailored to an individual patient
based on the genomic profile of a tumour. Despite the ever-increasing abundance of cancer …

Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF
has enabled a “precision medicine” paradigm to diagnose and treat BRAF-driven tumors …

Background BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed
the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …